Skip to NavigationSkip to content

European Parliament

EMA under fire from European Parliament

European Parliament
MEPs highlighted conflicts of interest and the independence of the regulator's drug evaluation experts

The EMA has been hit by a barrage of criticism from the European Parliament over conflicts of interest and the independence of its drug evaluation experts.

MEPs said there were no proper guarantees of the independence of experts hired to carry out scientific evaluations of medicines and that some of those evaluating Servier’s diabetes drug Mediator (benfluorex) had conflicting interests.

The damning report also voiced grave concerns with the European regulator’s management of procurement procedures and its lack of criteria for recruiting staff.

Europe tightens patient information proposals

European Parliament
MEPs want health professionals who give information on medicines at public events or in the media to declare any links they have to pharma

European restrictions on patient access to medicines information are still on track to be relaxed, but the proposed changes have been tightened up this week after further deliberation by the European Parliament.

MEPs said information on prescription medicines should be prohibited not only on television and radio, as proposed by the Commission, but also in print media.

They also want health professionals who give information on medicines at public events or in the media to declare any links they have to pharmaceutical companies.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches